N-(2-methoxybenzyl)phenethylamines (NBOMes) are a family of potent 5-HT2A agonists containing substances emerging on the illicit drug market as a replacement for N,N-diethyllysergamide (LSD). Despite the increasing use of NBOMes for diagnostic, research and recreational purposes, only a limited number of studies have focussed on their in vivo effect. Here, we investigated pharmacokinetics, systemic toxicity, thermoregulation in individually and group-housed animals, and acute behavioural effects after subcutaneous administration of 2,5-dimethoxy-4-(2-((2-methoxybenzyl)amino)ethyl)benzonitrile (25CN-NBOMe; 0.2, 1, and 5 mg/kg) in Wistar rats. Drug concentration peaked 1 h after the administration of 5 mg/kg in both blood serum and brain tissue with a half-life of 1.88 and 2.28 h, respectively. According to Organisation for Economic Co-operation and Development 423 toxicity assay, the drug is classified into category 3 with a lethal dose of 300 mg/kg and an estimated LD50 value of 200 mg/kg. Histological examination of organs collected from rats injected with the lethal dose revealed subtle pathological changes, highly suggestive of acute cardiovascular arrest due to malignant arrhythmia. Altered thermoregulation after 5 mg/kg was demonstrated by reduced body temperature in individually housed rats (p < 0.01). Behavioural effects assessed by the Open Field test and Prepulse Inhibition of Startle Response revealed that the two lower doses (0.2 and 1 mg/kg) caused a reduction in locomotor activity (p < 0.01), increased anxiety (p < 0.05) and 5 mg/kg additionally impaired sensorimotor gating (p < 0.001). In summary, 25CN-NBOMe readily passes the blood-brain barrier and exhibits a moderate level of toxicity and behavioural effect comparable with other NBOMes.

1st Faculty of Medicine Institute of Pathology Charles University Prague Czech Republic

3rd Faculty of Medicine Charles University Prague Czech Republic

Forensic Laboratory of Biologically Active Compounds Department of Chemistry of Natural Compounds University of Chemistry and Technology Prague Czech Republic

Psychedelics Research Centre National Institute of Mental Health Klecany Czech Republic

Zobrazit více v PubMed

Zawilska JB, Kacela M, Adamowicz P. NBOMes-highly potent and toxic alternatives of LSD. Front Neurosci. 2020;14:78. doi:10.3389/fnins.2020.00078

Poulie CBM, Jensen AA, Halberstadt AL, Kristensen JL. DARK Classics in Chemical Neuroscience: NBOMes. Published online 2019. 10.1021/acschemneuro.9b00528

Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology. 2015;99:546-553. doi:10.1016/j.neuropharm.2015.08.034

Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9(17):3897-3902. doi:10.1097/00001756-199812010-00024

Nichols DE, Sassano MF, Halberstadt AL, et al. N -Benzyl-5-methoxytryptamines as potent serotonin 5-HT2 receptor family agonists and comparison with a series of phenethylamine analogues. ACS Chem Nerosci. 2015;6(7):1165-1175. doi:10.1021/cn500292d

Suzuki J, Dekker MA, Valenti ES, et al. Toxicities associated with NBOMe ingestion-a novel class of potent hallucinogens: a review of the literature. Psychosomatics. 2015;56(2):129-139. doi:10.1016/j.psym.2014.11.002

Seo H, Kim IS, Kim YH, Yoo HH, Hong J. Metabolic profile determination of 25N-NBOMe in human liver microsomes by liquid chromatography-quadrupole time-of-flight mass spectrometry. Int J Leg Med. 2019;133(3):833-841. doi:10.1007/s00414-018-1904-7

Tylš F, Páleníček T, Horáček J. Psilocybin - summary of knowledge and new perspectives. Eur Neuropsychopharmacol. 2014;24(3):342-356. doi:10.1016/j.euroneuro.2013.12.006

Zuba D, Sekuła K, Buczek A. 25C-NBOMe - new potent hallucinogenic substance identified on the drug market. Forensic Sci Int. 2013;227(1-3):7-14. doi:10.1016/j.forsciint.2012.08.027

Hill SL, Doris T, Gurung S, et al. Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. Clin Toxicol. 2013;51(6):487-492. doi:10.3109/15563650.2013.802795

Laskowski LK, Elbakoush F, Calvo J, et al. Evolution of the NBOMes: 25C- and 25B- sold as 25I-NBOMe. J Med Toxicol. 2015;11(2):237-241. doi:10.1007/s13181-014-0445-9

Tang MHY, Ching CK, Tsui MSH, Chu FKC, Mak TWL. Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe. Clin Toxicol. 2014;52(5):561-565. doi:10.3109/15563650.2014.909932

Hansen M, Phonekeo K, Paine JS, Leth-petersen S, Begtrup M. Synthesis and structure − activity relationships of N - benzyl phenethylamines as 5 - HT. Published online 2014.

Hansen M. Design and synthesis of selective serotonin receptor agonists for positron emission tomography imaging of the brain. PhD thesis. København: Det Farmaceutiske Fakultet, 2010:1-207.

Šuláková A, Nykodemová J, Palivec P, Jurok R, Rimpelová S, Leonhardt T. 25CN-NBOMe metabolites in rat urine, human liver microsomes and C. elegans-structure determination and synthesis of the most abundant metabolites. Published online 2021.

Jensen AA, McCorvy JD, Leth-Petersen S, et al. Detailed characterization of the in vitro pharmacological and pharmacokinetic properties of N-(2-hydroxybenzyl)-2, 5-dimethoxy-4-cyanophenylethylamine (25CN-NBOH), a highly selective and brain-penetrant 5-HT2A receptor agonist. J Pharmacol Exp Ther. 2017;361(3):441-453. doi:10.1124/jpet.117.239905

Šíchová K, Pinterová N, Židková M, et al. Mephedrone (4-methylmethcathinone): acute behavioral effects, hyperthermic, and pharmacokinetic profile in rats. Front Psych. 2018;8(JAN):1-11. doi:10.3389/fpsyt.2017.00306

Štefková-Mazochová K, Danda H, Dehaen W, et al. Pharmacokinetic, pharmacodynamic, and behavioural studies of deschloroketamine in Wistar rats. Br J Pharmacol. 2022;179(1):65-83. doi:10.1111/bph.15680

Pinterova-Leca N, Horsley RR, Danda H, et al. Naphyrone (naphthylpyrovalerone): pharmacokinetics, behavioural effects and thermoregulation in Wistar rats. Addict Biol. 2021;26(2):1-9. doi:10.1111/adb.12906

Štefková K, Židková M, Horsley RR, et al. Pharmacokinetic, ambulatory, and hyperthermic effects of 3,4-methylenedioxy-n-methylcathinone (Methylone) in rats. Front Psych. 2017;8(NOV):1-11. doi:10.3389/fpsyt.2017.00232

Drago F, Nicolosi A, Micale V, Lo Menzo G. Placebo affects the performance of rats in models of depression: is it a good control for behavioral experiments? Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2001;11(3):209-213. doi:10.1016/s0924-977x(01)00084-0

Di Bartolomeo M, Stark T, Maurel OM, et al. Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: analyses in patients and in perinatal Δ9-tetrahydrocannabinol-exposed rats. Pharmacol Res. 2021;164:105357. doi:10.1016/j.phrs.2020.105357

Nakamura M, Shintani-Ishida K, Ikegaya H. 5-HT2A receptor agonist-induced hyperthermia is induced via vasoconstriction by peripheral 5-HT2A receptors and brown adipose tissue thermogenesis by peripheral serotonin loss at a high ambient temperature. J Pharmacol Exp Ther. 2018;367(2):356-362. doi:10.1124/jpet.118.250217

Páleníček T, Lhotková E, Žídková M, et al. Emerging toxicity of 5,6-methylenedioxy-2-aminoindane (MDAI): pharmacokinetics, behaviour, thermoregulation and LD50 in rats. Prog Neuro-Psychopharmacology Biol Psychiatry. 2016;69:49-59. doi:10.1016/j.pnpbp.2016.04.004

Herian M, Skawski M, Wojtas A, Sobocińska MK, Noworyta K, Gołembiowska K. Tolerance to neurochemical and behavioral effects of the hallucinogen 25I-NBOMe. Psychopharmacology (Berl). 2021;238(8):2349-2364. doi:10.1007/s00213-021-05860-5

Kawahara G, Maeda H, Kikura-Hanajiri R, Yoshida K, ichi, Hayashi YK. The psychoactive drug 25B-NBOMe recapitulates rhabdomyolysis in zebrafish larvae. Forensic Toxicol. 2017;35(2):369-375. doi:10.1007/s11419-017-0366-9

Gatch MB, Dolan SB, Forster MJ. Locomotor and discriminative stimulus effects of four novel hallucinogens in rodents. Behav Pharmacol. 2017;28(5):375-385. doi:10.1097/FBP.0000000000000309

Wojtas A, Herian M, Skawski M, et al. Neurochemical and behavioral effects of a new hallucinogenic compound 25B-NBOMe in rats. Neurotox Res. 2021;39(2):305-326. doi:10.1007/s12640-020-00297-8

Miliano C, Marti M, Pintori N, et al. Neurochemical and behavioral profiling in male and female rats of the psychedelic agent 25I-NBOMe. Front Pharmacol. 2019;10:1406. doi:10.3389/fphar.2019.01406

Rohanová M, Páleníček T, Balíková M. Disposition of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and its metabolite 4-bromo-2-hydroxy-5-methoxyphenethylamine in rats after subcutaneous administration. Toxicol Lett. 2008;178(1):29-36. doi:10.1016/j.toxlet.2008.01.017

Wijnand HP. Pharmacokinetic model equations for the one- and two-compartment models with first-order processes in which the absorption and exponential elimination or distribution rate constants are equal. J Pharmacokinet Biopharm. 1988;16(1):109-128. doi:10.1007/BF01061864

Buckeridge EM, Bull AMJ, McGregor AH. Biomechanical determinants of elite rowing technique and performance. Scand J Med Sci Sports. 2015;25(2):e176-e183. doi:10.1111/sms.12264

Páleníček T, Balíková M, Bubeníková-Valešová V, Horáček J. Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose. Psychopharmacology (Berl). 2008;196(1):51-62. doi:10.1007/s00213-007-0926-5

Kyriakou C, Marinelli E, Frati P, et al. NBOMe: new potent hallucinogens-pharmacology, analytical methods, toxicities, fatalities: a review. Eur Rev Med Pharmacol Sci. 2015;19(17):3270-3281.

Wood DM, Sedefov R, Cunningham A, Dargan PI. Prevalence of use and acute toxicity associated with the use of NBOMe drugs. Clin Toxicol. 2015;53(2):85-92. doi:10.3109/15563650.2015.1004179

Matuszewich L, Yamamoto BK. Long-lasting effects of chronic stress on doi-induced hyperthermia in male rats. Psychopharmacology (Berl). 2003;169(2):169-175. doi:10.1007/s00213-003-1498-7

Murakami N, Sakata Y. A possible role of the serotonergic system in thermoregulation in the rabbit. Neuropharmacology. 1980;19(9):891-895. doi:10.1016/0028-3908(80)90089-1

Elmore JS, Decker AM, Sulima A, et al. Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats. Neuropharmacology. 2018;142:240-250. doi:10.1016/j.neuropharm.2018.02.033

Eshleman AJ, Forster MJ, Wolfrum KM, Johnson RA, Janowsky A, Gatch MB. Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function. Psychopharmacology (Berl). 2014;231(5):875-888. doi:10.1007/s00213-013-3303-6

Halberstadt AL. Pharmacology and toxicology of N-benzylphenethylamine (“NBOMe”) hallucinogens. Curr Top Behav Neurosci. 2017;32:283-311. doi:10.1007/7854_2016_64

Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol. 2003;463(1-3):3-33. doi:10.1016/S0014-2999(03)01272-X

Bersani FS, Corazza O, Albano G, et al. 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. Biomed Res Int. 2014;2014:1-6. doi:10.1155/2014/734749

Halberstadt AL, Geyer MA. LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor. Psychopharmacology (Berl). 2010;208(2):179-189. doi:10.1007/s00213-009-1718-x

Páleníček T, Hliňák Z, Bubeníková-Valešová V, Novák T, Horáček J. Sex differences in the effects of N,N-diethyllysergamide (LSD) on behavioural activity and prepulse inhibition. Prog Neuro-Psychopharmacology Biol Psychiatry. 2010;34(4):588-596. doi:10.1016/j.pnpbp.2010.02.008

Sipes TA, Geyer MA. Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats. Neuropharmacology. 1994;33(3-4):441-448. doi:10.1016/0028-3908(94)90074-4

Páleníček T, Fujáková M, Brunovský M, et al. Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats. Psychopharmacology (Berl). 2013;225(1):75-93. doi:10.1007/s00213-012-2797-7

Halberstadt AL, Geyer MA. Effect of hallucinogens on unconditioned behavior. Curr Top Behav Neurosci. 2018;36:159-199. doi:10.1007/7854_2016_466

Acute pharmacological profile of 2C-B-Fly-NBOMe in male Wistar rats-pharmacokinetics, effects on behaviour and thermoregulation